Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Familial juvenile polyposis (FJP) is a hamartomatouspolyposis syndrome in which affected family members develop upper and lower gastrointestinal juvenile polyps and are at increased risk for gastrointestinal cancer. A genetic locus for FJP has not yet been identified by linkage; therefore, the objective of this study was to perform a focused genome screen in a large family segregating FJP. No evidence for linkage was found with markers near MSH2, MLH1, MCC, APC, HMPS, CDKN2A, JP1, PTEN, KRAS2,
TP53
, or
LKB1
. Linkage to FJP was established with several markers from chromosome 18q21.1. The maximum LOD score was 5.00, with marker D18S1099 (recombination fraction of .001). Analysis of critical recombinants places the FJP gene in an 11.9-cM interval bounded by D18S1118 and D18S487, a region that also contains the tumor-suppressor genes DCC and DPC4. These data demonstrate localization of a gene for FJP to chromosome 18q21.1 by linkage, and they raise the possibility that either DCC or DPC4 could be responsible for FJP.
...
PMID:A gene for familial juvenile polyposis maps to chromosome 18q21.1. 954 10
We herein summarize the reports on genetic changes in precancerous lesions in the gastrointestinal tract. It has been reported that with esophageal lesions such as dysplasia and Barrett's esophagus there is a high frequency of
p53
mutations. Among gastric lesions, some cases of chronic atrophic gastritis have been shown to harbor K-ras mutations.
p53
and APC mutations in intestinal metaplasia have also been demonstrated, as have APC mutations in flat adenomas. With colorectal lesions, it has been reported that K-ras, DCC,
p53
mutations commonly occur while APC mutations are also seen in cases of adenoma-carcinoma.
p53
and K-ras mutations have been demonstrated with serrated adenoma, and K-ras mutations with hyperplastic polyps APC mutations in familial polyposis coli,
LKB1
mutations in Peutz-Jeghers syndrome, and SMAD4/DPC4 mutations in juvenile polyposis syndrome have been found. Besides these genes, other genetic changes likely occur in carcinogenesis among those with hereditary diseases. K-ras mutations in aberrant crypt foci and hMSH2 mutations in ulcerative colitis have been found. Research into the genetic changes associated with cancerous lesions should lead to the development of early diagnosis and treatment methods for gastrointestinal cancer as well as the improved comprehension of carcinogenesis.
...
PMID:[Genome analyses for precancerous lesions in the gastrointestinal tract]. 1074 Jun 25
Peutz-Jeghers syndrome (PJS) is characterized by multiple gastrointestinal hamartomatous polyps, mucocutaneous melanin deposition, and increased risk of cancer, mainly in the gastrointestinal tract. We examined mutations of the
LKB1
, beta-catenin, APC, K-ras, and
p53
genes in 27 gastrointestinal hamartomatous polyps from 10 patients in nine PJS families. Of these hamartomatous polyps, one intestinal polyp had an adenomatous lesion, and one gastric polyp contained adenomatous and carcinomatous lesions. Germ-line mutations of the
LKB1
gene were detected in six PJS families. Somatic mutations of the
LKB1
gene were found in 5 polyps, whereas loss of heterozygosity (LOH) at the
LKB1
locus at 19p was seen in 14 other polyps. In adenomatous lesions microdissected from hamartomatous polyps, both beta-catenin mutation and 19p LOH were detected. Furthermore, a carcinomatous lesion in a gastric hamartomatous polyp was found to contain a mutation of the
p53
gene and LOH at the
p53
locus in addition to LOH at the
LKB1
locus and a beta-catenin mutation. K-ras mutations were detected in a few polyps, whereas no APC mutation or 5q LOH was detected in hamartomatous polyps. These results suggest that gastrointestinal hamartomatous polyps in PJS patients develop through inactivation of the
LKB1
gene by germ-line mutation plus somatic mutation or LOH of the unaffected
LKB1
allele, and that additional mutations of the beta-catenin gene and
p53
gene convert hamartomatous polyps into adenomatous and carcinomatous lesions.
...
PMID:Somatic mutations of LKB1 and beta-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome. 1110 90
Peutz-Jeghers syndrome is an inherited cancer syndrome that results in a greatly increased risk of developing tumors in those affected. The causative gene is a protein kinase termed
LKB1
, predicted to function as a tumor suppressor. The mechanism by which
LKB1
is regulated in cells is not known. Here, we demonstrate that stimulation of Rat-2 or embryonic stem cells with activators of ERK1/2 or of cAMP-dependent protein kinase induced phosphorylation of endogenously expressed
LKB1
at Ser(431). We present pharmacological and genetic evidence that p90(RSK) mediated this phosphorylation in response to agonists that activate ERK1/2 and that cAMP-dependent protein kinase mediated this phosphorylation in response to agonists that activate adenylate cyclase. Ser(431) of
LKB1
lies adjacent to a putative prenylation motif, and we demonstrate that full-length
LKB1
expressed in 293 cells was prenylated by addition of a farnesyl group to Cys(433). Our data suggest that phosphorylation of
LKB1
at Ser(431) does not affect farnesylation and that farnesylation does not affect phosphorylation at Ser(431). Phosphorylation of
LKB1
at Ser(431) did not alter the activity of
LKB1
to phosphorylate itself or the
tumor suppressor protein p53
or alter the amount of
LKB1
associated with cell membranes. The reintroduction of wild-type
LKB1
into a cancer cell line that lacks
LKB1
suppressed growth, but mutants of
LKB1
in which Ser(431) was mutated to Ala to prevent phosphorylation of
LKB1
were ineffective in inhibiting growth. In contrast, a mutant of
LKB1
that cannot be prenylated was still able to suppress the growth of cells.
...
PMID:Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell vrowth. 1129 20
Here, we investigate the mechanism and function of
LKB1
, a Ser/Thr kinase mutated in Peutz-Jegher syndrome (PJS). We demonstrate that
LKB1
physically associates with
p53
and regulates specific
p53
-dependent apoptosis pathways.
LKB1
protein is present in both the cytoplasm and nucleus of living cells and translocates to mitochondria during apoptosis. In vivo,
LKB1
is highly upregulated in pyknotic intestinal epithelial cells. In contrast, polyps arising in Peutz-Jegher patients are devoid of
LKB1
staining and have reduced numbers of apoptotic cells. We propose that a deficiency in apoptosis is a key factor in the formation of multiple benign intestinal polyps in PJS patients, and possibly for the subsequent development of malignant tumors in these patients.
...
PMID:The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. 1143 Aug 32
Germline mutations of the
LKB1
tumor suppressor gene lead to Peutz-Jeghers syndrome (PJS), with a predisposition to cancer.
LKB1
encodes for a nuclear and cytoplasmic serine/threonine kinase, which is inactivated by mutations observed in PJS patients. Restoring
LKB1
activity into cancer cell lines defective for its expression results in a G(1) cell cycle arrest. Here we have investigated molecular mechanisms leading to this arrest. Reintroduced active
LKB1
was cytoplasmic and nuclear, whereas most kinase-defective PJS mutants of
LKB1
localized predominantly to the nucleus. Moreover, when
LKB1
was forced to remain cytoplasmic through disruption of the nuclear localization signal, it retained full growth suppression activity in a kinase-dependent manner.
LKB1
-mediated G(1) arrest was found to be bypassed by co-expression of the G(1) cyclins cyclin D1 and cyclin E. In addition, the protein levels of the CDK inhibitor p21(WAF1/CIP1) and p21 promoter activity were specifically upregulated in
LKB1
-transfected cells. Both the growth arrest and the induction of the p21 promoter were found to be
p53
-dependent. These results suggest that growth suppression by
LKB1
is mediated through signaling of cytoplasmic
LKB1
to induce p21 through a
p53
-dependent mechanism.
...
PMID:Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). 1204 3
Germline mutations in
LKB1
(also known as STK11) are associated with Peutz-Jeghers syndrome (PJS), a disorder with predisposition to gastrointestinal polyposis and cancer. PJS polyps are unusual neoplasms characterized by marked epithelial and stromal overgrowth but have limited malignant potential. Here we show that Lkb1(+/-) mice develop intestinal polyps identical to those seen in individuals affected with PJS. Consistent with this in vivo tumour suppressor function, Lkb1 deficiency prevents culture-induced senescence without loss of Ink4a/Arf or
p53
. Despite compromised mortality, Lkb1(-/-) mouse embryonic fibroblasts show resistance to transformation by activated Ha-Ras either alone or with immortalizing oncogenes. This phenotype is in agreement with the paucity of mutations in Ras seen in PJS polyps and suggests that loss of Lkb1 function as an early neoplastic event renders cells resistant to subsequent oncogene-induced transformation. In addition, the Lkb1 transcriptome shows modulation of factors linked to angiogenesis, extracellular matrix remodelling, cell adhesion and inhibition of Ras transformation. Together, our data rationalize several features of PJS polyposis--notably its peculiar histopathological presentation and limited malignant potential--and place Lkb1 in a distinct class of tumour suppressors.
...
PMID:Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. 1222 50
The genomic alterations in preneoplastic lesions are summarized in this review. 3p and 9p in the lung, 9p in the bladder, 8p in the prostata, 19q and 1p in oligodendroglioma, and 22q in meningioma were reported to be deleted. Somatic mutation of
p53
was found in preneoplastic lesions of the esophagus, stomach, colon, thyroid, and astrocytoma. Adenoma-carcinoma sequence (Apc, ras,
p53
gene alterations) in colon,
LKB1
gene in Peutz-Jeghers syndrome, Smad4 in juvenile polyposis, hMSH2, hMLH1, PMS1, PMS2 genes in HNPCC, VHL gene in kidney, WT1 in Wilms tumor, RB gene in retinoblastoma, and ret gene in MEN were reportedly altered in preneoplastic lesions involved in hereditary tumors. Cervical dysplasia and papilloma of the head and neck infected by human papilloma virus and liver infected by B-type hepatitis virus are also precancerous. Genomic instability, APC gene alteration, point mutation of K-ras in preneoplastic lesions of stomach and K-ras and p16 alterations in metaplasia of pancreas were also found. Advances in research on genomic alterations in preneoplastic lesions will contribute to prevention and early detection of cancer.
...
PMID:[Genomic alterations in preneoplastic lesions]. 1250 66
Peutz-Jeghers Syndrome (PJS) is thought to be caused by mutations occurring in the widely expressed serine/threonine protein kinase named
LKB1
/STK11. Recent work has led to the identification of four mutants (R304W, I177N, K175-D176del, L263fsX286) and two novel aberrant
LKB1
/STK11 cDNA isoforms (r291-464del, r485-1283del) in a group of PJS Italian patients. Three of the four mutations only change 1 or 2 amino acids in the
LKB1
/STK11 catalytic domain. Here we demonstrate that all six
LKB1
/STK11 variants analysed are completely inactive in vitro as they were unable to autophosphorylate at Thr336, the major
LKB1
/STK11 autophosphorylation site, and to phosphorylate the
p53
tumour suppressor protein. We also show that 5 out of the 6 variants are entirely localised in the nucleus in contrast to the wild type
LKB1
/STK11, which is detected in both the nucleus and cytoplasm. Finally we demonstrate that all 6
LKB1
/STK11 variants, in contrast to wild type
LKB1
/STK11, are unable to suppress the growth of melanoma G361 cells. Taken together, these results demonstrate that the
LKB1
mutations investigated in this study lead to the loss of serine/threonine kinase activity and are therefore likely to be the primary cause of PJS development in the patients that they were isolated from.
...
PMID:Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers Syndrome patients. 1255 71
Germ-line mutations in
LKB1
gene cause the Peutz-Jeghers syndrome (PJS), a genetic disease with increased risk of malignancies. Recently,
LKB1
-inactivating mutations have been identified in one-third of sporadic lung adenocarcinomas, indicating that
LKB1
gene inactivation is critical in tumors other than those of the PJS syndrome. However, the in vivo substrates of
LKB1
and its role in cancer development have not been completely elucidated. Here we show that overexpression of wild-type
LKB1
protein in A549 lung adenocarcinomas cells leads to cell-growth suppression. To examine changes in gene expression profiles subsequent to exogenous wild-type
LKB1
in A549 cells, we used cDNA microarrays. We detected deregulation of 100 genes involved in cell proliferation, apoptosis, and cell adhesion. Strikingly, modification of the expression of well-known
p53
-responsive genes such as GADD45, TOP2A, and p21 suggests that growth suppression in A549 cells overexpressing
LKB1
may be mediated by
p53
. In addition, PTEN up-regulation indicates that
LKB1
could be involved in the PTEN/phosphatidylinositol-3'-kinase(PI3K)/AKT molecular pathway. Thus, our results give some insights into the understanding of how
LKB1
inactivation contributes to lung carcinogenesis.
...
PMID:Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphatidylinositol 3'-phosphate kinase/PTEN pathway. 1264 3
1
2
3
4
5
6
7
8
9
10
Next >>